Compare Abbott Laboratories (ABT) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Texas Instruments Incorporated — how do they compare? Abbott Laboratories trades at $95.16 (market cap $166.94B), while Texas Instruments Incorporated trades at $304.45 (market cap $266.93B). The key difference: Texas Instruments Incorporated is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | TXN | |
|---|---|---|
Market Cap | $166.94B | $266.93B |
Sector | Health | Technology |
52-Week High | $136.62 | $332.35 |
52-Week Low | $82.57 | $153.33 |
Enterprise Value | $193.69B | $275.88B |
Dividend Yield | 2.63% | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.18, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. The stock shows solid fundamentals with a P/E of 26.85, net income margin of 13.91%, and consistent dividend payments. Recent news highlights CE Mark approval for Libre Duo systems and positive diagnostic portfolio developments, supporting growth prospects in healthcare markets.
Outlook remains positive with a consensus price target of $122.55 implying 29% upside, though risks include competitive pressures and macroeconomic volatility. Earnings beat in Q1 2026 offsets prior misses, while cash flow stability and declining debt-to-asset ratio (15.02% in 2025) reinforce financial health. Institutional sentiment is strongly bullish with 75.6% buy ratings.
Texas Instruments (TXN) trades at $301.32, down 0.72% on the day, with technical indicators showing a bearish trend but recent news highlighting strong AI-driven demand. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in prior quarters, while maintaining robust profitability with a 29.11% net income margin. Revenue growth is recovering, projected to reach $18.4B in 2026, and the balance sheet shows solid liquidity with $7.58B in cash, though debt levels have risen.
Outlook: TXN benefits from AI infrastructure demand and operational leverage, but high valuation ratios (P/E 50.14) and rising debt pose risks. Analyst consensus is bullish with a $310.95 price target, suggesting modest upside potential. Key risks include competitive pressures and macroeconomic volatility affecting semiconductor cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
